(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 104.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 292.31%, and while it is forecast to beat the US market's average forecast revenue growth rate of 58.63%.
Soleno Therapeutics's revenue in 2025 is $98,675,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2025 to be $7,866,370,262, with the lowest SLNO revenue forecast at $5,764,696,983, and the highest SLNO revenue forecast at $9,925,612,620. On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $22,127,993,200, with the lowest SLNO revenue forecast at $13,273,895,579, and the highest SLNO revenue forecast at $31,119,051,385.
In 2027, SLNO is forecast to generate $36,589,417,431 in revenue, with the lowest revenue forecast at $22,821,926,723 and the highest revenue forecast at $46,954,915,156.